A new blood test may help predict early-stage breast cancer patients at highest risk for recurrence
https://www.facingourrisk.org/XRAY/breast-cancer-tool-predicts-recurrence-risk
Full article: https://jamanetwork.com/journals/jamaoncology/article-abstract/2740685
Which patients are at risk for a relapse of early-stage breast cancer? Tests to predict recurrence would help find people who need more monitoring after treatment and provide a chance to find and treat them earlier. This study looked at whether a blood test for tumor DNA (called circulating tumor DNA or ctDNA) is useful for finding people with recurrence earlier than current clinical practice. (11/4/19)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Given my breast cancer, what are my chances of relapse?
- What are the best ways I can be monitored for relapse?
- What are the signs or symptoms of relapse for my breast cancer?
- Should my primary tumor be DNA sequenced?
- Is it useful to monitor ctDNA or circulating tumor cells for my situation?
- How often should I have follow-up exams or mammography?
- Can you provide me with a survivorship care plan?
Open Clinical Trials
The following research studies are looking at liquid biopsy and cancer.
- NCT04962529 Breast cancer liquid biopsy trial. This study looks at whether a liquid biopsy test being developed is a less-invasive alternative to a tissue biopsy in patients with suspected metastatic breast cancer.
- NCT04567420: DNA-Guided Second Line Adjuvant Therapy For High-Residual Risk, Stage II-III, Hormone Receptor-Positive, HER2-Negative Breast Cancer. This study monitors people with early-stage, high-risk breast cancer for possible recurrence using a test called circulating tumor DNA (ctDNA). People who test positive for ctDNA but who have no other signs of recurrence, receive either the drugs palbociclib combined with fulvestrant or standard-of-care adjuvant hormone therapy.
- NCT03568630 Blood markers of early pancreas cancer. This study attempts to identify markers of early pancreatic cancer for screening individuals who are at higher-than-average risk.
- Validating a blood test for early ovarian cancer detection in high-risk women and families: microRNA detection study (MiDE). The MiDe study looks at whether a liquid biopsy can accurately detect early-stage ovarian cancer in women who are at high risk due to an inherited mutation.
Visit our Featured Research Page and Research Search and Enroll Tool to find additional studies enrolling people with or at high risk for cancer.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.